Combination Chemotherapy for the Treatment of Indian Kala-Azar - Full Text View

Sponsor:	Banaras Hindu University
Information provided by:	Banaras Hindu University
ClinicalTrials.gov Identifier:	NCT00370825

Purpose

The investigators are using a sequential design to combine miltefosine and AmBisome in different doses.

Condition	Intervention	Phase
Visceral Leishmaniasis	Drug: Combination therapy with AmBisome and miltefosine	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Official Title:	Combination Chemotherapy for the Treatment of Indian Visceral Leishmaniasis: Miltefosine Plus Liposomal Amphotericin B - Dose and Duration Ranging Study

Resource links provided by NLM:

MedlinePlus related topics: Leishmaniasis

Drug Information available for: Miltefosine Amphotericin B

U.S. FDA Resources

Further study details as provided by Banaras Hindu University:

Primary Outcome Measures:

Absence of clinical kala-azar at six month follow up

Estimated Enrollment:	200
Study Start Date:	September 2006

Detailed Description:

In this sequential design four arm study one arm is a reference arm but the three arms will consist an of initial dose of liposomal amphotericin B on first day followed by miltefosine. Both the drugs will be used in different doses. Reference arm will consist only a single dose of amBisome at 5 mg/kg. After the end of treatment, the post treatment assessment will be done on day 16 (initial cure) and six months (final cure). Safety parameters will be evaluated on day 0, 8 and 16. An arm with an efficacy of less than 75% will be closed. There will be periodical assessment of study results after completion of 5 patients in each arm.

Eligibility

Ages Eligible for Study:	12 Years to 65 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Clinical diagnosis of active VL with consistent signs and symptoms (e.g., fever, splenomegaly).
Confirmed diagnosis by bone-marrow or splenic aspirate smear showing characteristic amastigotes.
Male or female.
Ages 12 to 65 years.
Both newly diagnosed cases and patients who have received previous treatment (in the latter case a 2-week wash-out will be required before starting the study treatment).
WBC > 1,000/mm3.
Hemoglobin ≥ 4 g/dL

Exclusion Criteria:

Pregnancy or breast-feeding.
HIV positive serology.
ASAT, ALAT, AP ≥ 3 times upper limit of normal range.
Bilirubin ≥ 2 times upper limit of normal range.
Prothrombin time ≥ 5 seconds above control.
Serum creatinine or BUN ≥ 1.5 times upper limit of normal range.
Any medical condition or situation that compromises compliance with study procedures.
HIV

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00370825

Locations

India, Bihar
Kala-azar Medical Research Center
Muzaffarpur, Bihar, India, 842001

Sponsors and Collaborators

Banaras Hindu University

Investigators

Principal Investigator:

Shyam Sundar, MD

Banaras Hindu University

More Information

No publications provided by Banaras Hindu University

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis. 2008 Oct 15;47(8):1000-6.

Study ID Numbers:	KAMRC0601
Study First Received:	August 31, 2006
Last Updated:	September 11, 2008
ClinicalTrials.gov Identifier:	NCT00370825 History of Changes
Health Authority:	India: Ministry of Health

Keywords provided by Banaras Hindu University:

Visceral leishmaniasis
miltefosine
AmBisome
Combination

Additional relevant MeSH terms:

Leishmaniasis
Anti-Infective Agents
Protozoan Infections
Antiprotozoal Agents
Skin Diseases, Parasitic
Skin Diseases
Antineoplastic Agents
Miltefosine
Mastigophora Infections
Liposomal amphotericin B

Pharmacologic Actions
Skin Diseases, Infectious
Antiparasitic Agents
Antifungal Agents
Therapeutic Uses
Antibiotics, Antifungal
Leishmaniasis, Visceral
Sarcomastigophora Infections
Parasitic Diseases

ClinicalTrials.gov processed this record on February 08, 2010